Statins and the progression of age-related macular degeneration in the United States.

<h4>Purpose</h4>To study the effect of statin exposure on the progression from non-exudative to exudative age-related macular degeneration (AMD).<h4>Methods</h4>Retrospective cohort study of commercially insured patients diagnosed with non-exudative AMD (n = 231,888) from 200...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cassie A Ludwig, Daniel Vail, Nitya A Rajeshuni, Ahmad Al-Moujahed, Tatiana Rosenblatt, Natalia F Callaway, Malini Veerappan Pasricha, Marco H Ji, Darius M Moshfeghi
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/07271a77698a4554bd865cfc52fe3329
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:<h4>Purpose</h4>To study the effect of statin exposure on the progression from non-exudative to exudative age-related macular degeneration (AMD).<h4>Methods</h4>Retrospective cohort study of commercially insured patients diagnosed with non-exudative AMD (n = 231,888) from 2007 to 2015. Time-to-event analysis of the association between exposure to lipid-lowering medications and time from non-exudative AMD to exudative AMD diagnosis was conducted. Outcome measures included progression to exudative AMD, indicated by diagnosis codes for exudative AMD or procedural codes for intravitreal injections.<h4>Results</h4>In the year before and after first AMD diagnosis, 11,330 patients were continuously prescribed lipid-lowering medications and 31,627 patients did not take any lipid-lowering medication. Of those taking statins, 21 (1.6%) patients were on very-high-dose lipophilic statins, 644 (47.6%) on high-dose lipophilic statins, and 689 (50.9%) on low-dose lipophilic statins. We found no statistically significant relationship between exposure to low (HR 0.89, 95% CI 0.83 to 1.38) or high-dose lipophilic statins (HR 1.12, 95% CI 0.86 to 1.45) and progression to exudative AMD. No patients taking very-high-dose lipophilic statins converted from non-exudative to exudative AMD, though this difference was not statistically significant due to the subgroup size (p = .23, log-rank test).<h4>Conclusions</h4>No statistically significant relationship was found between statin exposure and risk of AMD progression. Interestingly, no patients taking very-high-dose lipophilic statins progressed to exudative AMD, a finding that warrants further exploration.